GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma
ObjectivePancreatic ductal adenocarcinoma (PDAC) is a highly malignant neoplasm with rising incidence worldwide. Gremlin 1 (GREM1), a regulator of bone morphogenetic protein (BMP) signaling, fine-tunes extensive biological processes, including organ morphology, cellular metabolism, and multiple path...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.968610/full |
| _version_ | 1817998056913633280 |
|---|---|
| author | Sen Yang Yalu Zhang Yalu Zhang Yuze Hua Ming Cui Mengyi Wang Junyi Gao Qiaofei Liu Quan Liao |
| author_facet | Sen Yang Yalu Zhang Yalu Zhang Yuze Hua Ming Cui Mengyi Wang Junyi Gao Qiaofei Liu Quan Liao |
| author_sort | Sen Yang |
| collection | DOAJ |
| description | ObjectivePancreatic ductal adenocarcinoma (PDAC) is a highly malignant neoplasm with rising incidence worldwide. Gremlin 1 (GREM1), a regulator of bone morphogenetic protein (BMP) signaling, fine-tunes extensive biological processes, including organ morphology, cellular metabolism, and multiple pathological developments. The roles of GREM1 in PDAC remain unknown.MethodsVarieties of public databases and online software were employed to analyze the expressions at transcription and protein levels of GREM1 in multiple malignant neoplasms including PDAC, and in addition, its potential pro-tumoral functions in PDAC were further evaluated. A total of 340 serum samples of pancreatic disease, including PDAC, low-grade malignant pancreatic neoplasm, benign pancreatic neoplasm, pancreatitis, and 132 healthy controls, were collected to detect GREM1. The roles of serum GREM1 in the diagnosis and prediction of survival of PDAC after radical resection were also analyzed.ResultsBioinformatics analyses revealed that GREM1 was overexpressed in PDAC and predicted a poorer survival in PDAC. A higher protein level of GREM1 in PDAC correlated with stroma formation and immunosuppression by recruiting varieties of immunosuppressive cells, including T regulatory cells (Tregs), M2 macrophages, myeloid-derived suppressor cells (MDSCs), and exhaustion T cells into the tumor microenvironment. A higher level of serum GREM1 was observed in PDAC patients, compared to healthy control (p < 0.001). Serum GREM1 had a good diagnostic value (area under the curve (AUC) = 0.718, p < 0.001), and its combination with carbohydrate antigen 199 (CA199) achieved a better diagnostic efficacy (AUC = 0.914, p < 0.001), compared to CA199 alone. The cutoff value was calculated by receiver operating characteristic (ROC) analysis, and PDAC patients were divided into two groups of low and high GREM1. Logistic analyses showed serum GREM1 positively correlated with tumor size (hazard ratio (HR) = 7.097, p = 0.032) and histopathological grades (HR = 2.898, p = 0.014). High-level serum GREM1 (1,117.8 pg/ml) showed a shorter postoperative survival (p = 0.0394).ConclusionHigher intra-tumoral expression of GREM1 in PDAC contributes to tumor stroma and immunosuppressive tumor microenvironment, presenting its therapeutic potential. High-level serum GREM1 predicts poorer survival after resection. A combination of serum CA199 and GREM1 shows a stronger diagnostic efficacy in PDAC. |
| first_indexed | 2024-04-14T02:47:30Z |
| format | Article |
| id | doaj.art-f58b63bc738345029e2fa509c93632d2 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-14T02:47:30Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-f58b63bc738345029e2fa509c93632d22022-12-22T02:16:27ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-08-011210.3389/fonc.2022.968610968610GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinomaSen Yang0Yalu Zhang1Yalu Zhang2Yuze Hua3Ming Cui4Mengyi Wang5Junyi Gao6Qiaofei Liu7Quan Liao8Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of General Surgery, Anhui Provincial Hospital, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, ChinaDepartment of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaObjectivePancreatic ductal adenocarcinoma (PDAC) is a highly malignant neoplasm with rising incidence worldwide. Gremlin 1 (GREM1), a regulator of bone morphogenetic protein (BMP) signaling, fine-tunes extensive biological processes, including organ morphology, cellular metabolism, and multiple pathological developments. The roles of GREM1 in PDAC remain unknown.MethodsVarieties of public databases and online software were employed to analyze the expressions at transcription and protein levels of GREM1 in multiple malignant neoplasms including PDAC, and in addition, its potential pro-tumoral functions in PDAC were further evaluated. A total of 340 serum samples of pancreatic disease, including PDAC, low-grade malignant pancreatic neoplasm, benign pancreatic neoplasm, pancreatitis, and 132 healthy controls, were collected to detect GREM1. The roles of serum GREM1 in the diagnosis and prediction of survival of PDAC after radical resection were also analyzed.ResultsBioinformatics analyses revealed that GREM1 was overexpressed in PDAC and predicted a poorer survival in PDAC. A higher protein level of GREM1 in PDAC correlated with stroma formation and immunosuppression by recruiting varieties of immunosuppressive cells, including T regulatory cells (Tregs), M2 macrophages, myeloid-derived suppressor cells (MDSCs), and exhaustion T cells into the tumor microenvironment. A higher level of serum GREM1 was observed in PDAC patients, compared to healthy control (p < 0.001). Serum GREM1 had a good diagnostic value (area under the curve (AUC) = 0.718, p < 0.001), and its combination with carbohydrate antigen 199 (CA199) achieved a better diagnostic efficacy (AUC = 0.914, p < 0.001), compared to CA199 alone. The cutoff value was calculated by receiver operating characteristic (ROC) analysis, and PDAC patients were divided into two groups of low and high GREM1. Logistic analyses showed serum GREM1 positively correlated with tumor size (hazard ratio (HR) = 7.097, p = 0.032) and histopathological grades (HR = 2.898, p = 0.014). High-level serum GREM1 (1,117.8 pg/ml) showed a shorter postoperative survival (p = 0.0394).ConclusionHigher intra-tumoral expression of GREM1 in PDAC contributes to tumor stroma and immunosuppressive tumor microenvironment, presenting its therapeutic potential. High-level serum GREM1 predicts poorer survival after resection. A combination of serum CA199 and GREM1 shows a stronger diagnostic efficacy in PDAC.https://www.frontiersin.org/articles/10.3389/fonc.2022.968610/fullgremlin 1 (GREM1)pancreatic adenocarcinoma (PDAC)tumor microenvironmentdiagnosismarker |
| spellingShingle | Sen Yang Yalu Zhang Yalu Zhang Yuze Hua Ming Cui Mengyi Wang Junyi Gao Qiaofei Liu Quan Liao GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma Frontiers in Oncology gremlin 1 (GREM1) pancreatic adenocarcinoma (PDAC) tumor microenvironment diagnosis marker |
| title | GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma |
| title_full | GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma |
| title_fullStr | GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma |
| title_full_unstemmed | GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma |
| title_short | GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma |
| title_sort | grem1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma |
| topic | gremlin 1 (GREM1) pancreatic adenocarcinoma (PDAC) tumor microenvironment diagnosis marker |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.968610/full |
| work_keys_str_mv | AT senyang grem1isanovelserumdiagnosticmarkerandpotentialtherapeutictargetforpancreaticductaladenocarcinoma AT yaluzhang grem1isanovelserumdiagnosticmarkerandpotentialtherapeutictargetforpancreaticductaladenocarcinoma AT yaluzhang grem1isanovelserumdiagnosticmarkerandpotentialtherapeutictargetforpancreaticductaladenocarcinoma AT yuzehua grem1isanovelserumdiagnosticmarkerandpotentialtherapeutictargetforpancreaticductaladenocarcinoma AT mingcui grem1isanovelserumdiagnosticmarkerandpotentialtherapeutictargetforpancreaticductaladenocarcinoma AT mengyiwang grem1isanovelserumdiagnosticmarkerandpotentialtherapeutictargetforpancreaticductaladenocarcinoma AT junyigao grem1isanovelserumdiagnosticmarkerandpotentialtherapeutictargetforpancreaticductaladenocarcinoma AT qiaofeiliu grem1isanovelserumdiagnosticmarkerandpotentialtherapeutictargetforpancreaticductaladenocarcinoma AT quanliao grem1isanovelserumdiagnosticmarkerandpotentialtherapeutictargetforpancreaticductaladenocarcinoma |